20 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
REGN
4 Jun 24
arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
REGN
4 Jun 24
. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
CRL
IQV
MAIA
31 May 24
. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com
n7p6ofh5uxzkvxxk46iibixg5ok1tm01qhqc8j3sxf5eqw7j99us8gsqy
REGN
17 May 24
, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam
95s76lmrmvg30dv44mtmg41tblp1yav9i0iy
REGN
3 May 24
antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi
kvxetx4gop kla8475v
REGN
2 May 24
, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing
xr2h42zb166v
REGN
30 Apr 24
in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has
9fazdozaf4og09sttyhddefbxx r4ltjqx46wyexrz
REGN
18 Apr 24
arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier
4ohz5aox
REGN
12 Apr 24
antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including
xzo9vm5nc62j3beqpi1
REGN
11 Apr 24
, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing
i0t f4rolr3v4raq
REGN
8 Apr 24
a complete response (CR) or better and 62% achieving a very good partial response (VGPR) or better, as determined by an independent review
so9mlgz62dp8ii7x7n793x7bkx7ae15wu 8qlncvl
REGN
7 Apr 24
by an independent review committee.1-month median time to response (range: <1-6 months). In responders, the median time to a VGPR
rl1n5 8lt0snvic
REGN
28 Mar 24
. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage
k2iv2fra 4g0f3x2oir
ARGX
ATNM
MRNA
28 Mar 24
is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com
ll53oafs6succis5i60k07oq7rb42b
REGN
26 Mar 24
and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology
frm 0fru7
ARGX
ATNM
AZN
26 Mar 24
, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative
ehrit2 dlo4upf
ARGX
ATNM
AZN
22 Mar 24
zero shares of ATNM. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent
yqz97cp0nwy 49019ijhtv6
REGN
20 Mar 24
developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new
- Prev
- 1
- Next